Designer bacteria as intratumoural enzyme biofactories
| Autor: | Glenn Hogan, Panos Lehouritis, Mark Tangney |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Genetic enhancement Enzyme Therapy Pharmaceutical Science Pharmacology Drug design Biological Factors 03 medical and health sciences Synthetic biology 0302 clinical medicine In vivo Neoplasms Chemotherapy Animals Humans Medicine Prodrugs Prodrug Cancer chemistry.chemical_classification R&D Bacteria biology business.industry Targeted Translational research biology.organism_classification 3. Good health 030104 developmental biology Enzyme chemistry 030220 oncology & carcinogenesis Cancer research Tumour business DEPT |
| Zdroj: | Advanced Drug Delivery Reviews. 118:8-23 |
| ISSN: | 0169-409X |
| DOI: | 10.1016/j.addr.2017.09.012 |
| Popis: | Bacterial-directed enzyme prodrug therapy (BDEPT) is an emerging form of treatment for cancer. It is a biphasic variant of gene therapy in which a bacterium, armed with an enzyme that can convert an inert prodrug into a cytotoxic compound, induces tumour cell death following tumour-specific prodrug activation. BDEPT combines the innate ability of bacteria to selectively proliferate in tumours, with the capacity of prodrugs to undergo contained, compartmentalised conversion into active metabolites in vivo. Although BDEPT has undergone clinical testing, it has received limited clinical exposure, and has yet to achieve regulatory approval. In this article, we review BDEPT from the system designer's perspective, and provide detailed commentary on how the designer should strategize its development de novo. We report on contemporary advancements in this field which aim to enhance BDEPT in terms of safety and efficacy. Finally, we discuss clinical and regulatory barriers facing BDEPT, and propose promising approaches through which these hurdles may best be tackled. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect